0 items / CHF0.00

<img src="https://legacypharmaceuticals.ch/wp-content/uploads/2022/02/legacy-pharmaceuticals-logo.png" alt="Legacy Pharmaceuticals" style="max-width: 180px;" />

<img src="https://legacypharmaceuticals.ch/wp-content/uploads/2022/02/legacy-pharmaceuticals-logo.png" alt="Legacy Pharmaceuticals" style="max-width: 180px;" />

0 items / CHF0.00

inlyta

Click to enlarge

Previous product

<img width="600" height="600" src="https://legacypharmaceuticals.ch/wp-content/uploads/2022/03/rybrevant_1-600x600.png" class="attachment-woocommerce_thumbnail size-woocommerce_thumbnail" alt="" srcset="https://legacypharmaceuticals.ch/wp-content/uploads/2022/03/rybrevant_1-600x600.png 600w, https://legacypharmaceuticals.ch/wp-content/uploads/2022/03/rybrevant_1-300x300.png 300w, https://legacypharmaceuticals.ch/wp-content/uploads/2022/03/rybrevant_1-150x150.png 150w, https://legacypharmaceuticals.ch/wp-content/uploads/2022/03/rybrevant_1.png 700w" sizes="(max-width: 600px) 100vw, 600px" />

Rybrevant (amivantamab-vmjw) CHF7,507.36

Back to products

Next product

Jemperli (dostarlimab) CHF19,355.72

Inlyta (axitinib)

CHF839.80

Inlyta (axitinib) is a prescription medicine used to treat kidney cancer (advanced renal cell carcinoma, also RCC). It is used as a single agent when 1 prior drug treatment regimen has not worked, or it is used as first-line treatment together with pembrolizumab or avelumab.

Add to wishlist

Category: Oncology

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Inlyta (axitinib)”

Start typing to see products you are looking for.

No account yet?

Create an Account